ArticlePloS one2025
Dementia risk estimation in persons at risk and the predictive turn in Alzheimer's disease-The PreTAD project: Study protocol with an ethical, clinical, linguistic, and legal approach.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dementia risk factor assessment in a local Alzheimer's prevention population: a German cross-sectional, observational study.The journal of prevention of Alzheimer's disease · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite progress in the field of Alzheimer's disease (AD) dementia risk estimation, little is known about its impact at the individual and societal levels.
objectiveIntroducing the explorative tri-national PreTAD project (The Predictive Turn in Alzheimer's Disease: Ethical, Clinical, Linguistic and Legal Aspects), which aims to (1) learn about attitudes, needs, and perspectives on AD dementia risk estimation of the general population and cognitively unimpaired individuals with and without contact to memory clinics, (2) identify anticipated impacts of AD dementia risk estimation and (3) discuss the implications of the paradigm shift in medicine at individual and societal levels from an ethical, linguistic and legal perspective.
methodsDifferent approaches are used: (1) an assessment of a population without experience with dementia, (2) an assessment in memory clinics, and (3) an online survey of the general population. Participants include cognitively healthy adults (n=2760), first-degree relatives of dementia patients (n=150), and participants with existing (n=150) and newly diagnosed (n=90) subjective cognitive decline (SCD) from Germany, Switzerland, and Spain.
resultsAs part of the PreTAD project, new questionnaires are developed that (1) collect attitudes, needs, and perspectives on AD dementia risk estimation and (2) assess anticipated impacts of dementia risk estimation using hypothetical blood-based biomarker dementia risk scenarios.
conclusionThe PreTAD study combines an interdisciplinary approach to develop a framework for predictive medicine in the preclinical stages of AD and supports improving communication of biomarker-based dementia risk estimation in clinical practice. The study was registered in the German Clinical Trials Register (DRKS00029035 on 03/08/2023).
trial registrationGerman clinical trials register (Deutsches Register Klinischer Studien, DRKS): http://www.drks.de/DRKS00029035, DRKS registration number: DRKS00029035, date of registration: 08.03.2023. Protocol version 3.0, date 01.06.2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.